NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Price Target & More

$166.98 -1.62 (-0.96 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$166.98
Today's Range$166.16 - $168.83
52-Week Range$103.75 - $184.79
Volume233,983 shs
Average Volume233,967 shs
Market Capitalization$3.58 billion
P/E Ratio64.97
Dividend YieldN/A
Beta0.91

About Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Debt-to-Equity Ratio0.05%
Current Ratio0.99%
Quick Ratio0.97%

Price-To-Earnings

Trailing P/E Ratio64.97
Forward P/E Ratio39.48
P/E Growth1.45

Sales & Book Value

Annual Sales$141.10 million
Price / Sales25.09
Cash Flow$3.7339 per share
Price / Cash44.72
Book Value$18.94 per share
Price / Book8.82

Profitability

EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Net Margins8.90%
Return on Equity14.44%
Return on Assets8.65%

Miscellaneous

Employees39
Outstanding Shares21,200,000

How to Become a New Pot Stock Millionaire

Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals (NASDAQ:LGND) released its quarterly earnings results on Wednesday, February, 21st. The biotechnology company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.19 by $0.12. The biotechnology company had revenue of $50.50 million for the quarter, compared to the consensus estimate of $49.39 million. Ligand Pharmaceuticals had a net margin of 8.90% and a return on equity of 14.44%. Ligand Pharmaceuticals's revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.25 EPS. View Ligand Pharmaceuticals' Earnings History.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Ligand Pharmaceuticals.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY18 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of $4.22 for the period, compared to the Thomson Reuters consensus estimate of $4.91. The company issued revenue guidance of $164 million, compared to the consensus revenue estimate of $166.87 million.

What price target have analysts set for LGND?

5 equities research analysts have issued twelve-month price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $105.00 to $200.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $159.00 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals.

What are Wall Street analysts saying about Ligand Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Ligand’s earnings and revenues beat estimates in fourth-quarter 2017. The company’s captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Additionally, the company’s entry into the Medical Devices Segment with the buyout of multiple programs owned by CorMatrix is encouraging. Shares of Ligand have outperformed the broader industry in the past year. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to these two products could leave a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtain Captisol is concerning." (2/28/2018)
  • 2. HC Wainwright analysts commented, "Kyprolis Beats; Recent and Anticipated Label Expansions Represent Revenue Inflection Points Kyprolis quickly approaching blockbuster status. Yesterday, partner Amgen (AMGN; not rated) announced 4Q17 and 2017 Kyprolis revenue of $227M and $835M, respectively, compared with our estimates of $220M (consensus $225M) and $828M. As Kyprolis approaches blockbuster status, considering certain factors we think should be able to easily push it over the edge, and they include: 1) recent FDA approval of sNDA based on ENDEAVOR overall survival data; 2) recent CHMP positive opinion to include updated overall survival from ENDEAVOR on label this year in the E.U.; and 3) recent submission of sNDA to FDA and a variation to the marketing authorization to the EMA, both based on the overall survival benefit from the ASPIRE study (actions expected this year). Upcoming milestones and key programs underway: 2018 initial visibility from recent launch of Baxdela for serious skin infections." (2/2/2018)

Who are some of Ligand Pharmaceuticals' key competitors?

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the folowing people:
  • Mr. John L. Higgins, Chief Exec. Officer and Exec. Director (Age 48)
  • Mr. Matthew W. Foehr, Pres and Chief Operating Officer (Age 45)
  • Mr. Matthew Korenberg, Exec. VP of Fin., CFO & Principal Accounting Officer (Age 43)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
  • Ms. Audrey Warfield-Graham, VP of HR

Has Ligand Pharmaceuticals been receiving favorable news coverage?

Press coverage about LGND stock has trended somewhat positive on Saturday, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a news sentiment score of 0.19 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include KNOTT DAVID M (4.10%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Melanie J Herman, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $166.98.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $3.58 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


MarketBeat Community Rating for Ligand Pharmaceuticals (LGND)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  334 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  526
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Ligand Pharmaceuticals in the last 12 months. Their average twelve-month price target is $159.00, suggesting that the stock has a possible downside of 4.78%. The high price target for LGND is $200.00 and the low price target for LGND is $105.00. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.602.75
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $159.00$159.00$147.80$139.00
Price Target Upside: 4.78% downside4.14% downside1.02% downside2.22% downside

Ligand Pharmaceuticals (NASDAQ:LGND) Consensus Price Target History

Price Target History for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2018HC WainwrightBoost Price TargetBuy -> Buy$170.00 -> $182.00MediumView Rating Details
3/7/2018Craig HallumReiterated RatingBuy$190.00 -> $200.00MediumView Rating Details
2/26/2018Roth CapitalBoost Price TargetBuy$158.00 -> $171.00LowView Rating Details
11/20/2017Deutsche BankDowngradeHold -> Sell$105.00N/AView Rating Details
8/9/2017StephensReiterated RatingOverweight$125.00 -> $137.00LowView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings History and Estimates Chart

Earnings by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings Estimates

Current Year EPS Consensus Estimate: $4.23 EPS
Next Year EPS Consensus Estimate: $5.08 EPS

Ligand Pharmaceuticals (NASDAQ LGND) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$0.57N/AView Earnings Details
2/21/2018Q4 2017$1.19$1.31$49.39 million$50.50 millionViewListenView Earnings Details
11/9/2017Q3 2017$0.37$0.69$31.04 million$33.38 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.25$0.67$24.40 million$28.00 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
8/8/2012Q2 2012($0.03)($0.20)ViewN/AView Earnings Details
5/2/2012Q1 2012$0.02($0.02)ViewN/AView Earnings Details
2/7/2012Q4 2011$0.02$0.24ViewN/AView Earnings Details
11/8/2011Q3 2011($0.20)ViewN/AView Earnings Details
8/8/2011Q2 2011$0.01($0.05)ViewN/AView Earnings Details
5/10/2011Q1 2011$0.04($0.06)ViewN/AView Earnings Details
2/15/2011Q4 2010$0.02$0.24ViewN/AView Earnings Details
11/9/2010Q3 2010($3.62)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.06($0.01)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.18)($0.15)ViewN/AView Earnings Details
2/9/2010Q4 2009$0.07ViewN/AView Earnings Details
11/5/2009Q3 2009($0.30)($0.18)ViewN/AView Earnings Details
8/3/2009Q2 2009($0.42)($0.22)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.24)($0.29)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.36)($0.11)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.42)($0.31)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.12)($0.61)ViewN/AView Earnings Details
2/20/2008Q4 2007$0.24($0.34)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ligand Pharmaceuticals (NASDAQ:LGND) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018John W KozarichDirectorSell2,500$160.43$401,075.00View SEC Filing  
3/12/2018Stephen L SabbaDirectorSell622$180.73$112,414.0626,363View SEC Filing  
3/9/2018Jason AryehDirectorSell7,500$175.73$1,317,975.0058,625View SEC Filing  
3/5/2018John L LamattinaDirectorSell3,335$160.90$536,601.5024,291View SEC Filing  
2/27/2018Todd C DavisDirectorSell17,170$152.37$2,616,192.9065,898View SEC Filing  
2/23/2018Jason AryehDirectorSell3,417$155.00$529,635.0058,625View SEC Filing  
2/23/2018Matthew W FoehrCOOSell5,444$152.98$832,823.1295,835View SEC Filing  
2/15/2018John L HigginsCEOSell9,000$157.03$1,413,270.00102,700View SEC Filing  
1/24/2018John L HigginsCEOSell22,500$165.00$3,712,500.00111,700View SEC Filing  
1/19/2018John L HigginsCEOSell28,099$153.70$4,318,816.30162,299View SEC Filing  
1/10/2018John W KozarichDirectorSell2,500$145.00$362,500.0033,149View SEC Filing  
12/20/2017Stephen L SabbaDirectorSell925$137.25$126,956.2526,985View SEC Filing  
11/17/2017Matthew E KorenbergVPSell6,559$142.63$935,510.178,147View SEC Filing  
11/16/2017John L HigginsCEOSell5,269$142.53$750,990.57143,542View SEC Filing  
11/16/2017John W KozarichDirectorSell5,000$141.71$708,550.0035,649View SEC Filing  
9/5/2017John L HigginsCEOSell5,000$130.00$650,000.00144,171View SEC Filing  
8/23/2017Jason AryehDirectorSell2,000$127.99$255,980.0059,625View SEC Filing  
8/9/2017Charles S BerkmanVPSell18,625$126.96$2,364,630.0024,423View SEC Filing  
8/9/2017Matthew W FoehrInsiderSell6,100$127.51$777,811.00101,020View SEC Filing  
8/8/2017John L HigginsCEOSell5,483$125.00$685,375.00144,654View SEC Filing  
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00143,837View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00151,171View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.7258,959View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.2098,341View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00139,171View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.8197,599View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.0058,959View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.4958,959View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.4058,959View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00122,664View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.0039,983View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.4040,783View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.0041,783View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.0042,883View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.0043,361View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.003,297View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.0058,337View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.0043,911View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.0044,711View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.0083,062View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.2258,337View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51120,220View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.0449,711View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.003,151View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.0032,536View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.0021,356View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.0063,743View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.8031,243View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.0053,457View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.0044,929View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.0017,667View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.0063,743View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.4226,936View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.2917,928View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00116,581View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.0024,166View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ligand Pharmaceuticals (NASDAQ LGND) News Headlines

Source:
DateHeadline
Calitheras Kidney Cancer Candidate Gets Fast Track StatusCalithera's Kidney Cancer Candidate Gets Fast Track Status
www.zacks.com - April 19 at 5:14 PM
Calithera's Kidney Cancer Candidate Gets Fast Track StatusCalithera's Kidney Cancer Candidate Gets Fast Track Status
finance.yahoo.com - April 19 at 5:14 PM
Agios Leukemia Drug Bodes Well for Growth & Strong PipelineAgios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
www.msn.com - April 18 at 5:20 PM
Ligand Pharmaceuticals (LGND) Cut to "Hold" at BidaskClubLigand Pharmaceuticals (LGND) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 14 at 5:18 PM
BRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR AgreementBRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement
www.reuters.com - April 14 at 8:52 AM
Ligand Pharmaceuticals (LGND) Expected to Announce Quarterly Sales of $32.32 MillionLigand Pharmaceuticals (LGND) Expected to Announce Quarterly Sales of $32.32 Million
www.americanbankingnews.com - April 14 at 3:54 AM
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell TherapyFDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
finance.yahoo.com - April 12 at 5:08 PM
Ligand Pharmaceuticals (LGND) Expected to Post Earnings of $1.28 Per ShareLigand Pharmaceuticals (LGND) Expected to Post Earnings of $1.28 Per Share
www.americanbankingnews.com - April 12 at 9:14 AM
Ligand Pharmaceuticals (LGND) Receives "Overweight" Rating from StephensLigand Pharmaceuticals (LGND) Receives "Overweight" Rating from Stephens
www.americanbankingnews.com - April 11 at 6:13 PM
First Week of November 16th Options Trading For Ligand Pharmaceuticals (LGND)First Week of November 16th Options Trading For Ligand Pharmaceuticals (LGND)
www.nasdaq.com - April 11 at 5:05 PM
Ligand Pharmaceuticals (LGND) Rating Increased to Hold at ValuEngineLigand Pharmaceuticals (LGND) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM
5 Best Profitable Stocks Offering Amazing Returns5 Best Profitable Stocks Offering Amazing Returns
finance.yahoo.com - April 11 at 9:09 AM
Ionis (IONS) Clinches Licensing Agreement with AstraZenecaIonis (IONS) Clinches Licensing Agreement with AstraZeneca
finance.yahoo.com - April 10 at 5:07 PM
Zacks Investment Research Downgrades Ligand Pharmaceuticals (LGND) to HoldZacks Investment Research Downgrades Ligand Pharmaceuticals (LGND) to Hold
www.americanbankingnews.com - April 7 at 4:58 PM
Ligand Pharmaceuticals (LGND) Given a $157.00 Price Target at HC WainwrightLigand Pharmaceuticals (LGND) Given a $157.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 5 at 7:58 PM
Ligand Pharmaceuticals (LGND) Director Sells $401,075.00 in StockLigand Pharmaceuticals (LGND) Director Sells $401,075.00 in Stock
www.americanbankingnews.com - April 3 at 10:26 PM
EMA Accepts Regeneron/Sanofi's application for DupixentEMA Accepts Regeneron/Sanofi's application for Dupixent
finance.yahoo.com - April 3 at 5:06 PM
Ligand Pharmaceuticals (LGND) Raised to "Buy" at ValuEngineLigand Pharmaceuticals (LGND) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 12:44 PM
Ligand Pharmaceuticals (LGND) Stock Rating Reaffirmed by HC WainwrightLigand Pharmaceuticals (LGND) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 1 at 7:35 PM
Ligand Pharmaceuticals (LGND) Given Consensus Recommendation of "Buy" by AnalystsLigand Pharmaceuticals (LGND) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 31 at 8:11 AM
HC Wainwright Analysts Give Ligand Pharmaceuticals (LGND) a $169.00 Price TargetHC Wainwright Analysts Give Ligand Pharmaceuticals (LGND) a $169.00 Price Target
www.americanbankingnews.com - March 30 at 10:36 PM
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio CompaniesLigand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
finance.yahoo.com - March 30 at 5:07 PM
BidaskClub Lowers Ligand Pharmaceuticals (LGND) to BuyBidaskClub Lowers Ligand Pharmaceuticals (LGND) to Buy
www.americanbankingnews.com - March 25 at 12:16 AM
Ligand Pharma amends sparsentan sublicense agreement with RetrophinLigand Pharma amends sparsentan sublicense agreement with Retrophin
seekingalpha.com - March 22 at 5:12 PM
Ignore Trump's Pricing Rhetoric With These 5 Biotech PicksIgnore Trump's Pricing Rhetoric With These 5 Biotech Picks
finance.yahoo.com - March 21 at 9:38 AM
Herons Pain Candidate Meets Endpoint in Pivotal StudiesHeron's Pain Candidate Meets Endpoint in Pivotal Studies
finance.yahoo.com - March 20 at 4:54 PM
Heron's Pain Candidate Meets Endpoint in Pivotal StudiesHeron's Pain Candidate Meets Endpoint in Pivotal Studies
finance.yahoo.com - March 20 at 4:54 PM
Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares UpGeron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up
finance.yahoo.com - March 19 at 4:54 PM
Today’s Research Reports on Trending Tickers: Ligand Pharmaceuticals and Portola PharmaceuticalsToday’s Research Reports on Trending Tickers: Ligand Pharmaceuticals and Portola Pharmaceuticals
finance.yahoo.com - March 19 at 8:53 AM
AbbVies Uterine Fibroids Candidate Succeeds in Phase IIIAbbVie's Uterine Fibroids Candidate Succeeds in Phase III
finance.yahoo.com - March 14 at 6:33 PM
Stephen L. Sabba Sells 622 Shares of Ligand Pharmaceuticals Inc. (LGND) StockStephen L. Sabba Sells 622 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock
www.americanbankingnews.com - March 13 at 8:32 PM
Aradigm Files MAA for Bronchiectasis Candidate in the EUAradigm Files MAA for Bronchiectasis Candidate in the EU
finance.yahoo.com - March 12 at 12:17 PM
Ligand Pharmaceuticals Inc. (LGND) Expected to Post Quarterly Sales of $25.99 MillionLigand Pharmaceuticals Inc. (LGND) Expected to Post Quarterly Sales of $25.99 Million
www.americanbankingnews.com - March 11 at 8:50 AM
Ligand Pharmaceuticals (LGND) Upgraded at BidaskClubLigand Pharmaceuticals (LGND) Upgraded at BidaskClub
www.americanbankingnews.com - March 11 at 12:16 AM
Ligand Pharmaceuticals Inc. (LGND) Director Sells $1,317,975.00 in StockLigand Pharmaceuticals Inc. (LGND) Director Sells $1,317,975.00 in Stock
www.americanbankingnews.com - March 9 at 9:15 PM
Corcept Plans Korlym Label Expansion, Pipeline in ProgressCorcept Plans Korlym Label Expansion, Pipeline in Progress
finance.yahoo.com - March 9 at 8:58 AM
Ligand Pharmaceuticals Inc. (LGND) Expected to Post Earnings of $0.65 Per ShareLigand Pharmaceuticals Inc. (LGND) Expected to Post Earnings of $0.65 Per Share
www.americanbankingnews.com - March 9 at 5:24 AM
How This Biotech Is Worth $3.5 Billion Without Selling One DrugHow This Biotech Is Worth $3.5 Billion Without Selling One Drug
finance.yahoo.com - March 8 at 8:54 AM
Ligand Pharmaceuticals (LGND) Price Target Increased to $182.00 by Analysts at HC WainwrightLigand Pharmaceuticals (LGND) Price Target Increased to $182.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 7 at 4:10 PM
Craig Hallum Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)Craig Hallum Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)
www.americanbankingnews.com - March 7 at 12:44 PM
Ligand Pharmaceuticals Inc. (LGND) Director Sells $536,601.50 in StockLigand Pharmaceuticals Inc. (LGND) Director Sells $536,601.50 in Stock
www.americanbankingnews.com - March 6 at 9:26 PM
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant SciencesLigand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
finance.yahoo.com - March 6 at 5:21 PM
Ligand Pharmaceuticals Inc. (LGND) Receives Average Rating of "Buy" from AnalystsLigand Pharmaceuticals Inc. (LGND) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 1:38 PM
Ligand Pharmaceuticals Inc. (LGND) Stake Lifted by Rhumbline AdvisersLigand Pharmaceuticals Inc. (LGND) Stake Lifted by Rhumbline Advisers
www.americanbankingnews.com - March 6 at 10:52 AM
FDA Accepts Regeneron/Sanofis Dupixent sBLA for AsthmaFDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
www.msn.com - March 5 at 5:31 PM
FDA Accepts Regeneron/Sanofi's Dupixent sBLA for AsthmaFDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
finance.yahoo.com - March 5 at 5:31 PM
Ligand Pharmaceuticals Inc. (LGND) Stake Raised by BlackRock Inc.Ligand Pharmaceuticals Inc. (LGND) Stake Raised by BlackRock Inc.
www.americanbankingnews.com - March 5 at 5:08 AM
Martingale Asset Management L P Raises Holdings in Ligand Pharmaceuticals Inc. (LGND)Martingale Asset Management L P Raises Holdings in Ligand Pharmaceuticals Inc. (LGND)
www.americanbankingnews.com - March 4 at 12:42 PM
State of Wisconsin Investment Board Has $2.78 Million Holdings in Ligand Pharmaceuticals Inc. (LGND)State of Wisconsin Investment Board Has $2.78 Million Holdings in Ligand Pharmaceuticals Inc. (LGND)
www.americanbankingnews.com - March 4 at 9:31 AM
Apple, Micron Lead 5 Top Tech Stocks For Aggressive Traders As S&P 500, Dow Jones StruggleApple, Micron Lead 5 Top Tech Stocks For Aggressive Traders As S&P 500, Dow Jones Struggle
finance.yahoo.com - March 4 at 8:46 AM

SEC Filings

Ligand Pharmaceuticals (NASDAQ:LGND) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ligand Pharmaceuticals (NASDAQ:LGND) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ligand Pharmaceuticals (NASDAQ LGND) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.